Výsledky vyhledávání

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer

Autor: S J, Knox, M L, Goris, M, Tempero, P L, Weiden, L, Gentner, H, Breitz, G P, Adams, D, Axworthy, S, Gaffigan, K, Bryan, D R, Fisher, D, Colcher, I D, Horak, L M, Weiner

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 6(2)

A Phase II study of yttrium-90-tetra-azacyclododecanetetra-acetic acid-biotin (90Y-DOTA-biotin) pretargeted by NR-LU-10 antibody/streptavidin (SA) was performed. The primary objectives of the study were to evaluate the efficacy and safety of this the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::962d544ea1d060a1e6383268f4555b29
https://pubmed.ncbi.nlm.nih.gov/10690517

Zobrazit plný text záznamu

Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy

Autor: T. Ciuleanu, B. A. Schaeffler, Y. Demidchik, M. Samarzjia, R. L. De Jager, S. V. Orlov, V. Beliakouski, D. L. Bentsion, M. Rancic, H. Breitz

Publikováno v: Journal of Clinical Oncology. 28:7002-7002

7002^ Background: Picoplatin is a new platinum compound designed to overcome platinum resistance and has demonstrated less neurotoxicity and nephrotoxicity than other platinum agents. The SPEAR study was designed to assess the efficacy and safety of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3d3bd9896ede89c4f556ae2983594726
https://doi.org/10.1200/jco.2010.28.15_suppl.7002

Zobrazit plný text záznamu

Abstract B49: FOLPI (picoplatin/5-fluorouracil/leucovorin) versus modified FOLFOX-6 as a neuropathy-sparing first-line therapy for colorectal cancer (CRC)

Autor: Oleg Gladkov, Robert De Jager, H. Breitz, S. Cheporov, Mikhail Biakhov, Robert H. Earhart

Publikováno v: Molecular Cancer Therapeutics. 8:B49-B49

Introduction: Picoplatin (Pico) was designed to overcome platinum resistance and has the potential for improved safety compared to other platinum agents. FOLFOX (5-FU, LV, oxaliplatin [oxali]) treatment for advanced CRC has dose-limiting oxali-relate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::10e5f9d613510f889ecec4ed86c966a5
https://doi.org/10.1158/1535-7163.targ-09-b49

Zobrazit plný text záznamu

Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)

Autor: R. L. De Jager, N. D. Lopatkin, L. Roman, Robert H. Earhart, P. Karlov, H. Breitz

Publikováno v: Journal of Clinical Oncology. 27:5140-5140

5140 Background: Picoplatin (Pico) was designed to overcome platinum resistance and has the potential for improved safety compared to other platinum agents. Previously, a PSA response rate of 25% was observed when Pico monotherapy was infused at 120

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ca5477666f8f47c60ba041dd7f1de3b
https://doi.org/10.1200/jco.2009.27.15_suppl.5140

Zobrazit plný text záznamu

Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC)

Autor: R. L. De Jager, Robert H. Earhart, S. Cheporov, Oleg Gladkov, M. Biakhov, H. Breitz

Publikováno v: Journal of Clinical Oncology. 27:4026-4026

4026 Background: Picoplatin (Pico) was designed to overcome platinum resistance and has the potential for improved safety compared to other platinum agents. FOLFOX (5-FU, LV, oxaliplatin [oxali]) treatment for advanced CRC has dose-limiting oxali- re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::205a63698d798c5efc8f239dce3af9e1
https://doi.org/10.1200/jco.2009.27.15_suppl.4026

Zobrazit plný text záznamu

166Ho-DOTMP Skeletal Targeted Radiotherapy with melphalan and autologous stem cell support for multiple myeloma

Autor: H. Breitz, Sergio Giralt, Donna Salzman, K. Ruffner, Mark Goodman, William I. Bensinger

Publikováno v: Journal of Clinical Oncology. 22:6656-6656

6656 Background: 166Ho-DOTMP is a radiotherapeutic that localizes specifically to the skeleton and can deliver high dose radiation to the bone and marrow for skeletal targeted radiotherapy (STR). Follow-up data from 3 clinical trials of patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f809cb0a62976c5c3a6a983ef6494ed8
https://doi.org/10.1200/jco.2004.22.90140.6656

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání